Advertisement

Topics

GlycoMimetics, Inc. and International AIDS Vaccine Initiative and Glycosensors and Diagnostics, LLC Company Profile

21:59 EDT 21st June 2018 | BioPortfolio

IAVI is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world. Founded in 1996, IAVI works with partners in 25 countries to research, design and develop AIDS vaccine candidates. In addition, IAVI conducts policy analyses and serves as an advocate for the AIDS vaccine field. IAVI supports a comprehensive approach to addressing HIV and AIDS that balances the expansion and strengthening of existing HIV-prevention and treatment programs with targeted investments in the design and development of new tools to prevent HIV. IAVI is dedicated to ensuring that a future AIDS vaccine will be available and accessible to all who need it. IAVI’s Innovation Fund supports the application of novel and unconventional technologies to AIDS vaccine design and development, and is partially supported by the Bill & Melinda Gates Foundation. IAVI relies on the generous donations from governments, private individuals, corporations and foundations to carry out its mission. For more information, see www.iavi.org.


News Articles [2428 Associated News Articles listed on BioPortfolio]

Global HIV/AIDS Diagnostics Market 2017-2022 – HIV/HIV-1/2/Combo, HIVAg/ NAT, Western Blot, HTLV-I/II – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global HIV/AIDS Diagnostics Market 2017-2022” report has been added to ResearchAndMarkets.com’s offering. Global HIV/AIDS Diagnostics Market 2...

World marks HIV Vaccine Awareness Day – New Vision

New VisionWorld marks HIV Vaccine Awareness DayNew VisionVACCINE FOR HIV. HEALTH- Twenty-one years ago today, Bill Clinton, American president then, said: “It is no longer a question of whether we c...

Share offering brings in $119M for GlycoMimetics

The sale of 7 million shares priced at $17 raised $119 million for GlycoMimetics.  -More- 

[Comment] The Lancet Commission on malaria eradication

20 years ago, infectious diseases dominated the global health agenda. Policy makers, researchers, implementers, and donors united in the fight against infectious diseases, creating the Millennium Deve...

NIH Chipping Away at Secrets to AIDS Immunity, Vaccines

New studies by National Institute of Allergy and Infectious Diseases (NIAID) scientists and grantees are helping to fill in pieces of the AIDS vaccine research puzzle...

GlycoMimetics unveils design for late-stage trial of leukemia candidate GMI-1271

The details of GlycoMimetics' design for its Phase III study to assess the efficacy and safety of its candidate GMI-1271 com -More- 

GlycoMimetics, Dutch foundation to initiate trial for blood cancer candidate

GlycoMimetics and the Haemato Oncology Foundation for Adults in the Netherlands will initiate a trial later this year to eval -More- 

Acute Coronary Syndrome (ACS): Strategies in Anticoagulant Selection: Diagnostics Approaches – Genetic Testing Aids vs. Biomarkers (Troponin types and BNP)

Acute Coronary Syndrome (ACS): Strategies in Anticoagulant Selection: Diagnostics Approaches – Genetic Testing Aids vs. Biomarkers (Troponin types and BNP) Curator: Aviva Lev-Ari, PhD, RN A bre...

PubMed Articles [2495 Associated PubMed Articles listed on BioPortfolio]

Detection of rotavirus before and after monovalent rotavirus vaccine introduction and vaccine effectiveness among children in mainland Tanzania.

Monovalent rotavirus vaccine (RV1) was introduced in Tanzania in January 2013 under the Reach Every Child initiative, to be given at ages 6 and 10 weeks. We used the sentinel hospital rotavirus surv...

Outside in - inside out. Creating focus on the patient - a vaccine company perspective.

Involving patients in the development of medicines and vaccines should result in benefits to patients. The vaccine recipient is usually a healthy person. We describe the rationale and implementation o...

Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation.

HIV-1 infection leads to chronic inflammation and to an increased risk of non-AIDS mortality. Our objective was to determine whether AIDS-defining events (ADEs) were associated with increased overall ...

Acute hepatitis A breakthrough in MSM in Paris area: implementation of targeted hepatitis A virus vaccine in a context of vaccine shortage.

Therapeutic HIV-1 vaccine: time for immunomodulation and combinatorial strategies.

The purpose is to recall some of the key immunological elements that are at the crossroad and need to be combined for developing a potent therapeutic HIV-1 vaccine.

Clinical Trials [5426 Associated Clinical Trials listed on BioPortfolio]

Evaluation of the Safety of a Polyvalent Virus in Healthy Adults

This is a research study to evaluate the safety of a vaccine to protect people from HIV infection. Human Immunodeficiency Virus (HIV) is the cause of AIDS (Acquired Immune Deficiency Syndr...

Diagnostics and Pharmacotherapy for Severe Forms of TB (DMID 15-0100)

Major Research Aim: To study novel molecular diagnostics and the pharmacokinetic variability among a spectrum of TB disease states, including severe forms of TB like disseminated TB, TB me...

Development of a New HIV Vaccine

The purpose of the study is to determine the safety of a new HIV vaccine and to evaluate the immune response to the vaccine. Only some HIV genes are used to make the vaccine and therefore...

Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention

The Mother-Daughter Initiative (MDI) will test the feasibility and acceptability of a strategy to deliver comprehensive cervical cancer prevention services in Thailand and the Philippines ...

Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan)

This trial studies the safety and immunogenicity of a HIV clade B'/C DNA vaccine followed by recombinant vaccinia virus rTV boost in HIV-uninfected healthy volunteers at low or high risk o...

Companies [2927 Associated Companies listed on BioPortfolio]

GlycoMimetics, Inc. and International AIDS Vaccine Initiative and Glycosensors and Diagnostics, LLC

IAVI is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world. Found...

IAVI

The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV ...

International AIDS Vaccine Initiative

The International AIDS Vaccine Initiative (IAVI)

The International AIDS Vaccine Initiative

More Information about "GlycoMimetics, Inc. and International AIDS Vaccine Initiative and Glycosensors and Diagnostics, LLC" on BioPortfolio

We have published hundreds of GlycoMimetics, Inc. and International AIDS Vaccine Initiative and Glycosensors and Diagnostics, LLC news stories on BioPortfolio along with dozens of GlycoMimetics, Inc. and International AIDS Vaccine Initiative and Glycosensors and Diagnostics, LLC Clinical Trials and PubMed Articles about GlycoMimetics, Inc. and International AIDS Vaccine Initiative and Glycosensors and Diagnostics, LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of GlycoMimetics, Inc. and International AIDS Vaccine Initiative and Glycosensors and Diagnostics, LLC Companies in our database. You can also find out about relevant GlycoMimetics, Inc. and International AIDS Vaccine Initiative and Glycosensors and Diagnostics, LLC Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record